With the profits from this product, Schering was able to diversify and one again try the U.S. The company used its expertise in steroids to produce the first birth control pill, simply known as "the Pill," introduced to the European market in 1961. Schering AG struggled to rebuild its business during the difficult conditions that prevailed following the war. As a result, the U.S.-based Schering Corporation was separated from Schering AG. government, and some ten years later the government elected to sell the business to a private investment group headed by Merrill Lynch. When Germany and the United States were once again pitted against one another in World War II, the company came under scrutiny, largely because its corporate parent was suspected of working closely with the Nazis to produce drugs that might help German pilots to withstand the strains of high altitudes, thus giving them the tactical advantage of being able to fly higher. market in 1929 by establishing New York City-based Schering Corporation, a subsidiary that focused on hormone research and synthesized steroid drugs. However, 40 years later during World War I when the United States and Germany became enemies, the German-owned subsidiary was dissolved. A subsidiary, Schering & Glatz, was launched in 1876 to distribute medicines produced by the parent company. From its earlier days, the company was active in the United States. In the 1930s it merged with a mining and chemical company and the resulting entity was renamed Schering AG. Over the next few decades, the company diversified into such areas as electroplating for decorative metals, industrial and laboratory chemicals, and agrochemicals. In 1890, a year after Schering died, the company launched its first specialty product, a treatment for gout. He would incorporate the business in 1871 as Chemische Fabrik auf Actien and become involved in the production of chemicals, such as mercury compounds, that had uses in both pharmaceuticals and photography. Generating about $1.2 billion in annual sales, Berlex contributes about one-quarter of its parent corporation's total revenues.Īlthough Berlex was founded in 1979, the roots of the company date back to the mid-19th century when Ernest Schering open a pharmacy in Berlin, Germany. Berlex's bioscience division is located in Richmond, California. The company also offers diagnostic imaging agents used in performing MRI scans. Berlex markets some 20 products, such as an oral contraceptive called Yasmin and medicines used to treat multiple sclerosis, dermatological disorders, and cancer. is a Montville, New Jersey-based subsidiary of German pharmaceutical Schering AG. NAIC: 325412 Pharmaceutical Preparation Manufacturingīerlex's singular approach to developing and making specialized medicines already has yielded innovations in treating multiple sclerosis, dermatological disorders, female health concerns, cancer and in the creation of new diagnostic imaging techniques.ġ988: Trademark suit settled with U.S.-based Schering Corporation.ġ990: Biotech Codon and Triton Biosciences acquired.ġ997: Headquarters is moved to Montville, New Jersey.īerlex Laboratories, Inc.
0 kommentar(er)
